Agf Management LTD Bristol Myers Squibb CO Transaction History

Agf Management LTD

$20.6 Billion
Q2 2025

A detailed history of Agf Management LTD transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Agf Management LTD holds 587,740 shares of BMY stock, worth $26.2 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

587,740

Previous 579,719 1.38%

Holding current value

$26.2 Million

Previous $35.4 Million 23.05%

% of portfolio

0.13%

Previous 0.2%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 06, 2025	BUY	$44.12 - $59.6 $353,886 - $478,051	8,021 Added 1.38%	587,740 $27.2 Million
Q1 2025 May 12, 2025	SELL	$53.9 - $63.11 $1.47 Million - $1.73 Million	-27,345 Reduced 4.5%	579,719 $35.4 Million
Q4 2024 Feb 07, 2025	BUY	$51.92 - $59.94 $2.38 Million - $2.75 Million	45,901 Added 8.18%	607,064 $34.3 Million
Q3 2024 Nov 12, 2024	BUY	$39.66 - $51.75 $191,557 - $249,952	4,830 Added 0.87%	561,163 $29 Million
Q2 2024 Aug 07, 2024	SELL	$40.25 - $52.99 $852,776 - $1.12 Million	-21,187 Reduced 3.67%	556,333 $23.1 Million
Q1 2024 May 13, 2024	SELL	$47.98 - $54.4 $834,852 - $946,560	-17,400 Reduced 2.92%	577,520 $31.3 Million
Q4 2023 Feb 07, 2024	BUY	$48.48 - $57.85 $383,185 - $457,246	7,904 Added 1.35%	594,920 $30.5 Million
Q3 2023 Nov 13, 2023	SELL	$57.89 - $64.73 $811,907 - $907,838	-14,025 Reduced 2.33%	587,016 $34.1 Million
Q2 2023 Aug 09, 2023	SELL	$63.71 - $70.74 $929,082 - $1.03 Million	-14,583 Reduced 2.37%	601,041 $38.4 Million
Q1 2023 May 03, 2023	SELL	$65.71 - $74.53 $522,263 - $592,364	-7,948 Reduced 1.27%	615,624 $42.7 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $42.7 Million - $50.6 Million	623,572 New	623,572 $0

Others Institutions Holding BMY

# of Institutions

2,660

Shares Held

1.64B

Call Options Held

22.4M

Put Options Held

25.4M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $94.7B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Agf Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Agf Management LTD with notifications on news.

Account

Agf Management LTD Bristol Myers Squibb CO Transaction History